Safety of PSMA-targeted molecular radioligand therapy with ¹⁷⁷Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262543

By:

• Calais, Jeremie;
• Czernin, Johannes;
• Thin, Pan;
• Gartmann, Jeannine;
• Nguyen, Kathleen;
• Armstrong, Wesley R;
• Allen-Auerbach, Martin;
• Quon, Andrew;
• Bahri, Shadfar;
• Gupta, Pawan 5;
• Gardner, Linda;
• Dahlbom, Magnus;
• He, Beilei;
• Esfandiari, Rouzbeh;
• Ranganathan, David;
• Herrmann, Ken;
• Eiber, Matthias;
• Fendler, Wolfgang P.;
• Delpassand, Ebrahim

Publication type:

Article